ADHD Life Expectancy: What the 2025 UK Study Found

First, this is not a countdown

The life-expectancy figures in this article describe differences between groups in one study. They do not tell you how long you will live.

The study does not show that ADHD symptoms directly remove a fixed number of years, that everyone with ADHD has the same risk, or that a late diagnosis means damage cannot be reduced. It identifies an important health inequality that needs better understanding and care.

If this topic is causing suicidal thoughts or you cannot stay safe, use the urgent actions in the guide to ADHD and suicidal thoughts now.

What the 2025 UK study found

The British Journal of Psychiatry study used UK primary-care records and included 30,039 adults with a recorded ADHD diagnosis. Each was matched by age, sex and primary-care practice with 10 adults who did not have a recorded ADHD diagnosis.

Using observed mortality rates and a period life-table method, the researchers estimated:

• males with diagnosed ADHD: life expectancy was 6.78 years shorter, with a 95% confidence interval from 4.50 to 9.11 years
• females with diagnosed ADHD: life expectancy was 8.64 years shorter, with a 95% confidence interval from 6.55 to 10.91 years

These are estimates with uncertainty, not exact losses experienced by each participant.

The limitations matter

The top-line figures are serious, but they should not be separated from the study design.

It studied recorded diagnosis, not everyone with ADHD

Only 0.32% of adults in the source data had a recorded ADHD diagnosis, far below expected population prevalence. The authors noted that diagnosed adults may differ from the much larger group whose ADHD is not recorded.

People who received a diagnosis during the study period may have had more severe or complex needs. That could make the estimated gap different from the gap across all adults who meet ADHD criteria.

It was observational

The study found a difference between groups. It could not prove that ADHD itself caused the deaths or establish the contribution of each possible pathway.

Recorded physical-health conditions, mental-health conditions, smoking and potentially harmful alcohol use were more common in the diagnosed ADHD group at baseline. These factors are important, but the study was not designed to say how much each one caused the life-expectancy difference.

It did not establish the effect of treatment

The researchers could not assess how medication, psychological treatment or other support changed life expectancy. The study should therefore not be used to claim that treatment restores a particular number of years.

A period estimate is not an individual forecast

The life-table method applies mortality rates observed during a period to a hypothetical population. It does not follow one person from age 18 until death or calculate their personal lifespan.

Where the older 13-year claim came from

An earlier estimate associated with Russell Barkley used a longitudinal childhood sample and statistical modelling of health and behavioural risk factors. It was valuable for drawing attention to long-term health, but it was not a direct observation that untreated ADHD removes 13 years from every person.

The 2025 UK paper is different because it used recorded mortality in a large primary-care dataset. Neither study gives an individual deadline. Headlines that combine their largest figures or attach them to "untreated ADHD" without explaining the methods are misleading.

Why might mortality be higher?

The UK study did not identify a single cause. Researchers and previous studies point to several possible contributors that need further investigation.

Mental health and suicide

Depression, anxiety, self-harm and other mental health conditions were more commonly recorded in the diagnosed ADHD group. These conditions deserve their own assessment and treatment. Read the source-checked guides to ADHD and depression and ADHD and anxiety for UK care routes.

Substance use

Smoking and potentially harmful alcohol use were more commonly recorded in the ADHD group. ADHD can also coexist with substance use disorders. The guide to ADHD and addiction explains specialist support and medication considerations without treating substance use as a simple dopamine problem.

Accidents and safety

Inattention, impulsive decisions and co-occurring conditions may affect risk in driving, work and other environments. The appropriate response is a personal safety assessment and reasonable adjustments, not assuming that every person with ADHD is unsafe.

Physical health and access to care

Managing appointments, prescriptions, screening, sleep and long-term conditions requires planning and follow-through. Executive-function difficulties can create practical barriers, but access, poverty, stigma, service design and other social factors also matter.

It would be inaccurate to reduce the life-expectancy difference to poor personal choices. Health outcomes reflect a combination of clinical, social and healthcare-system factors.

Does ADHD treatment reduce mortality?

A 2024 Swedish observational study compared outcomes after a new ADHD diagnosis using a target-trial emulation approach. Starting ADHD medication was associated with lower 2-year all-cause mortality and lower mortality from unnatural causes. It was not associated with a statistically clear reduction in natural-cause mortality.

This is encouraging evidence, but it does not prove that medication caused the difference. Treatment groups can differ in ways that are difficult to measure, and the study did not calculate life-expectancy years.

Medication decisions should be based on ADHD symptoms, impairment, benefits, risks, health history and personal preference with a qualified prescriber. Do not start, stop or change medicine because of mortality headlines.

NICE ADHD guidance recommends ongoing monitoring and review according to the severity of the condition. The UK ADHD medication guide explains the usual pathway and monitoring checks.

Practical health priorities

There is no special anti-mortality checklist for ADHD. The useful approach is to make ordinary evidence-based healthcare easier to access and follow.

Keep ADHD care reviewed

Attend medication monitoring and broader ADHD follow-up. Tell the clinician about side effects, missed doses, new health conditions, mental-health changes, alcohol or drug use and any difficulty following the plan.

Use routine healthcare

Follow NHS invitations and clinical advice for vaccinations, screening and long-term condition reviews. Ask a GP which checks are appropriate for your age, history, symptoms and medicines instead of ordering a generic package of tests from an article.

Address mental health early

Persistent depression, severe anxiety, substance use, self-harm and suicidal thoughts need proper assessment. These are not signs that someone has failed to manage ADHD.

Make appointments easier to complete

Practical supports can include:

• booking the next review before leaving
• using calendar alerts with travel or preparation time
• keeping one current medication list
• requesting written instructions
• using a repeat-prescription reminder
• asking a trusted person to help if you want them involved

Review driving and work safety honestly

Tell the relevant clinician if symptoms or medication affect safe driving, machinery, shift work or another safety-sensitive task. Adjustments and treatment review are more useful than shame or concealment.

Where mentoring fits

ADHD mentoring cannot assess mortality risk, treat a health condition, prescribe medicine or extend life expectancy. Claims that mentoring prevents early death would be unsupported.

When someone is stable and has appropriate healthcare, mentoring may help with practical executive-function barriers such as calendars, appointment preparation, prescription routines and breaking clinician-agreed health actions into manageable steps.

If that non-clinical scope fits your needs alongside healthcare, you can book a free 15-minute discovery call. Personal health risks should be discussed with a GP or relevant specialist.

Key points

• The 2025 UK study found a substantial group-level life-expectancy gap in adults with recorded ADHD.
• Diagnosed adults in the dataset may not represent everyone with ADHD.
• The study did not establish causes or the effect of treatment.
• Earlier 13-year claims came from a different modelling method.
• Medication initiation has been associated with lower short-term mortality in observational research, but causation is not proven.
• Better access to ADHD, mental-health, substance-use and routine healthcare is the practical priority.

This article was source-checked on 29 July 2026 against the primary UK study, NICE and NHS guidance, and peer-reviewed medication research. It is general information and has not been reviewed by an epidemiologist, psychiatrist or GP.